000			05298cam a2200433Mi 4500
001			96286
003			ES-MaUEC
005			20230102112747.0
006			m o d
007			cr |n|||||||||
008			170626s2017 xx o 000 0 eng d
020			_a9402409513 _q(electronic bk.)
020			_a9789402409512 _q(electronic bk.)
020			_z9402409491
020			_z9789402409499
040			_aYDX _cYDX _dN$T _dEBLCP _dGW5XE _dUAB _dAZU _dUPM _dOCLCF _dMERER _dESU _dOCLCQ _dCOO _dOCLCQ _dIOG _dJG0 _dES-MaUEC _bspa
050		4	_aRC280.S8 _bG378 2017 EB
245	0	0	_aGastric cancer prewarning and early diagnosis system _cDaxiang Cui, editor.
250			_a1st ed. 2017.
264		1	_a[Lugar de publicación no identificado] _bSpringer _c2017.
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF
490	0		_aTranslational Medicine Research _x2451-991X
500			_aSpringerLink _bSpringer Biomedical and Life Sciences eBooks 2017 English+International
505	0		_aPreface; Contents; Chapter 1: Background of Gastric Cancer Prewarning and Early Diagnosis System; 1.1 Current Clinical Status of Gastric Cancer; 1.2 Main Diagnostic Methods for Gastric Cancer in the Clinical Setting; 1.2.1 Endoscopy; 1.2.2 Imaging Diagnosis; 1.2.3 Histopathological Examination; 1.2.4 Serological Biomarker Examination; 1.3 Concept of Gastric Cancer Prewarning and Early Diagnosis System; References; Chapter 2: Human Serum Protein Markers for Gastric Cancer Detection; 2.1 Introduction; 2.2 Broad-Spectrum Tumor Serum Markers in the Detection of Gastric Cancer; 2.2.1 CEA.
505	8		_a2.2.2 CA19-92.2.3 CA125; 2.2.4 AFP; 2.2.5 M2-Pyruvate Kinase; 2.3 Gastric Secreted Protein as Serum Markers of Gastric Cancer; 2.3.1 PGI; 2.3.2 PGII; 2.3.3 Gastrin 17; 2.3.4 TFF3; 2.4 Gastric Infection and Gastric Cancer-Associated Antibodies; 2.4.1 H. pylori Antibody; 2.4.2 CagA Antibody; 2.4.3 p53 Antibody; 2.4.4 Anti-parietal Cell Antibody; 2.5 Inflammation Signaling Molecules in the Diagnosis of Gastric Cancer; 2.5.1 SAA (Serum Amyloid A); 2.5.2 MIF (Macrophage Migration Inhibitory Factor); 2.5.3 Leptin; 2.5.4 Dickkopf; 2.5.5 Olfactomedin 4; 2.5.6 VAP-1 (Vascular Adhesion Protein-1).
505	8		_a2.6 Protease and Protease Inhibitors in the Diagnosis of Gastric Cancer2.6.1 UPA; 2.6.2 Cathepsin B; 2.6.3 HMW Kininogen; 2.7 Apoptosis-Related Molecules; 2.7.1 Cytokeratin 18; 2.8 Cell Division-Related Molecules; 2.8.1 RegIV; 2.8.2 S100A6; 2.8.3 IPO-38; 2.9 Plasma Coagulation Factors; 2.9.1 Thrombin Light Chain A; 2.9.2 Fibrinopeptide A; 2.10 Conclusions; References; Chapter 3: Screening and Detection of Gastric Cancer Circulating MicroRNA Biomarkers; 3.1 MicroRNA and Gastric Cancer; 3.1.1 MicroRNA; 3.1.2 MicroRNA and Gastric Cancer; 3.2 Circulating MicroRNA Biomarkers for Gastric Cancer.
505	8		_a3.2.1 Background3.2.2 Advantages on Circulating MicroRNA Biomarkers; 3.2.3 Correlation Between Tissue miRNAs and Circulating miRNAs; 3.2.4 Challenges on Screening of Circulating MicroRNA Biomarkers; 3.2.5 Circulating MicroRNA Biomarkers for Gastric Cancer; 3.2.6 Conclusions and Prospects; 3.3 Nanoparticle-Based Optical Detection of MicroRNA; 3.3.1 Background; 3.3.2 Characteristics of MicroRNA Detection; 3.3.3 Fluorescence-Based MicroRNA Detection; 3.3.3.1 Quantum Dots; 3.3.3.2 Silver Nanoclusters; 3.3.3.3 Magnetic Nanoparticles and Others; 3.3.4 Scattering-Based MicroRNA Detection.
505	8		_a3.3.4.1 SERS3.3.4.2 Other Scattering; 3.3.5 Colorimetry-Based MicroRNA Detection; 3.3.6 Conclusions and Outlook; References; Chapter 4: Screening and Identification of Biomarkers from Gastric Cancer Saliva Metabolites; 4.1 Introduction; 4.2 Molecular Identification in Saliva of Gastric Cancer Patients; 4.3 Biomarkers in Saliva of Gastric Cancer Patients and Metabolic Characteristics; 4.4 Diagnosis of Gastric Cancer Using the Identified Biomarkers; 4.5 Saliva Markers for Gastric Cancer Detection; References.
520	3		_aThe book explores recent developments in the application of nanotechnology in the early detection of gastric cancer. It discusses various aspects, such as screening for gastric cancer-associated biomarkers; establishing new ultrasensitive detection methods based on nanoparticle labeling and nanoeffects; developing a new generation of nanodevices for high-throughput examination of serum and breath biomarkers; developing multifunctional nanoprobes for targeted imaging and simultaneous therapy of gastric cancer; evaluating the biosafety of multifunctional nanoprobes; and the establishment of a pre-warning and early diagnosis system. It also presents clinical applications and prospects. The book provides a valuable reference for researchers in nanomedicine and clinicians involved in gastric cancer and radiology.
650		7	_aBiotecnología _2embne _0(OCoLC)fst01894713 _0 _9140931
700	1		_aCui, Daxiang.
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-94-024-0951-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aEBOOK, asignarmaterias, EBSPRINGER_2017D
998			_b02/2018 _dz _e- _zSI
999			_c96286 _d96286 _x1